Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, Caroline, Long, Georgina V., Brady, Benjamin, Dutriaux, Caroline, Maio, Michele, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J., Hernberg, Micaela M., Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Arance, Ana, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Lundgren-Eriksson, Lotta, Horak, Christine, Sharkey, Brian, Waxman, Ian M., Atkinson, Victoria, Ascierto, Paolo A.·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1412082

Cited by (1,032)

Items 801–900 of 1,032

  1. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients
    Margarita García, Rafael Moreno, Marta Gil-Martín, Manel Cascalló, María Ochoa de Olza, Carmen Cuadra, Josep Maria Piulats, Valentín Navarro, Marta Doménech, Ramón Alemany et al. · 2018 · Human Gene Therapy
  2. PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
    Shijie Xu, Fangbo Cui, Dafu Huang, Dinghu Zhang, Anqing Zhu, Xia Sun, Yiming Cao, Sheng Ding, Yao Wang, Eryun Gao et al. · 2018 · International Journal of Nanomedicine
  3. Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
    Subhadwip Basu, Jeffrey Yang, Bin Xu, Katarzyna Magiera‐Mularz, Łukasz Skalniak, Bogdan Musielak, Vladyslav V. Kholodovych, Tad A. Holak, Longqin Hu · 2019 · Journal of Medicinal Chemistry
  4. Cutaneous melanoma and the immunotherapy revolution (Review)
    Giulia Costanza Leonardi, Saverio Candido, Luca Falzone, Demetrios A. Spandidos, Massimo Libra · 2020 · International Journal of Oncology
  5. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure
    Ziying Lin, Lixia Huang, Shaoli Li, Jincui Gu, Xiaoxian Cui, Yanbin Zhou · 2020 · Scientific Reports
  6. mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
    Maryam Bidram, Yue Zhao, Natalia G. Shebardina, Alexey V. Baldin, Alexandr V. Bazhin, Mohamad Reza Ganjalikhany, Andrey A. Zamyatnin, Mazdak Ganjalıkhani-Hakemi · 2021 · Vaccines
  7. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
    Sophie C. Postel-Vinay, Sandrine Aspeslagh, Émilie Lanoy, Caroline Robert, Jean‐Charles Soria, Aurélien Marabelle · 2015 · Annals of Oncology
  8. Immune‐Related Adverse Events From Immune Checkpoint Inhibitors
    Kristen Ashley Marrone, W Ying, Jarushka Naidoo · 2016 · Clinical Pharmacology & Therapeutics
  9. High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
    Shoichiro Horita, Yayoi Nomura, Yumi Sato, Tatsuro Shimamura, So Iwata, Norimichi Nomura · 2016 · Scientific Reports
  10. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
    Michael Ryan Cassidy, Rachel E. Wolchok, Junting Zheng, Katherine S. Panageas, Jedd D. Wolchok, Daniel G. Coit, Michael Andrew Postow, Charlotte Eielson Ariyan · 2017 · EBioMedicine
  11. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study
    Lawson Eng, Rinku Sutradhar, Yue Niu, Ning Liu, Ying Liu, Yosuf Kaliwal, Melanie Powis, Geoffrey Liu, Jeffrey M. Peppercorn, Philippe Lucien Bedard et al. · 2023 · Journal of Clinical Oncology
  12. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials
    Marco Donia, Marie Louise Kimper-Karl, Katrine Lundby Høyer, Lars Bastholt, Henrik Schmidt, Inge Marie Svane · 2017 · European Journal of Cancer
  13. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review
    Markus Vincent Heppt, Theresa Steeb, Justin Gabriel Schlager, Stefanie Rosumeck, Corinna Dressler, Thomas Ruzicka, Alexander Nast, Carola Berking · 2017 · Cancer Treatment Reviews
  14. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
    Deborah T. Blumenthal, Michal Yalon, Gilad Wolf Vainer, Alexander Lossos, Shlomit Yust, Tzach Lior, Emanuela Cagnano, Dror Limon, Felix Bokstein · 2016 · Journal of Neuro-Oncology
  15. Recent developments with immunotherapy for hepatocellular carcinoma
    Oliver Waidmann · 2018 · Expert Opinion on Biological Therapy
  16. Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials
    Bo Zhang, Qiong Wu, You Lang Zhou, Xinyu Guo, Jun Ge, Jiaji Fu · 2018 · International Immunopharmacology
  17. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond
    Yang Zhao, Junfeng Du, Xiaofei Shen · 2023 · Frontiers in Immunology
  18. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
    Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J. et al. · 2021 · Annals of Oncology
  19. A second chance for telomerase reverse transcriptase in anticancer immunotherapy
    Maurizio Zanetti · 2016 · Nature Reviews Clinical Oncology
  20. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
    Saskia Herz, Thomas Höfer, Matina Papapanagiotou, Julia Leyh, Sarah Meyenburg, Dirk Schadendorf, Selma Ugurel, Alexander Roesch, Elisabeth Livingstone, Bastian Schilling et al. · 2016 · European Journal of Cancer
  21. The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
    Andrew M. K. Law, Elgene Lim, Christopher John Ormandy, David Gallego‐Ortega · 2017 · Endocrine Related Cancer
  22. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
    Sagun Parakh, John Park, Shehara Ramyalini Mendis, Rajat Rai, Wen Xu, Serigne Lo, Martin Drummond, Catherine E Rowe, Annie Ngai Man Wong, Grant A. McArthur et al. · 2017 · British Journal of Cancer
  23. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma
    Chunyan Hao, Jinhui Tian, Huiling Liu, Fei Li, Hongxia Niu, Bingdong Zhu · 2017 · Medicine
  24. Targeting innate sensing in the tumor microenvironment to improve immunotherapy
    Zhida Liu, Chuanhui Han, Yang‐Xin Fu · 2019 · Cellular and Molecular Immunology
  25. Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy
    Xiaoying Sun, Na Zhang, Chengqian Yin, Bo Zhu, Xin Li · 2020 · Frontiers in Oncology
  26. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis
    Congzhou Mike Sha, Eric J. Lehrer, Clara Hwang, Daniel Michael Trifiletti, Heath B. Mackley, Joseph J. Drabick, Nicholas George Zaorsky · 2020 · Radiotherapy and Oncology
  27. Therapeutic Cancer Vaccines
    Jeffrey Schlom, James W. Hodge, Claudia Palena, Kwong-Yok Tsang, Caroline Jochéms, John W. Greiner, Benedetto Farsaci, Ravi Amrit Madan, Christopher Ryan Heery, James L. Gulley · 2014 · Advances in cancer research
  28. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
    Mehmet Asım Bilen, Sumit Kumar Subudhi, Jianjun Gao, Nizar M. Tannir, Shi‐Ming Tu, Padmanee Sharma · 2016 · Journal for ImmunoTherapy of Cancer
  29. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
    Kevin Joseph Harrington, Robert H.I. Andtbacka, Frances A. Collichio, Gerald F. Downey, Lisa Chen, Zsolt Roland Szabó, Howard L. Kaufman · 2016 · OncoTargets and Therapy
  30. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
    Silvana Morello, Mariaelena Capone, Claudia Sorrentino, Diana Giannarelli, Gabriele Madonna, Domenico Mallardo, Antonio Maria Grimaldi, Aldo Pinto, Paolo A. Ascierto · 2017 · Journal of Translational Medicine
  31. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
    Matthew C Perez, John Thomas Miura, Syeda Mahrukh Hussnain Naqvi, Youngchul Kim, Amanda H. Holstein, Daniel H. Lee, Amod A. Sarnaik, Jonathan S. Zager · 2018 · Annals of Surgical Oncology
  32. Base excision repair regulates PD-L1 expression in cancer cells
    Tiara Bunga Mayang Permata, Yoshihiko Hagiwara, Hiro Sato, Takaaki Yasuhara, Takahiro Oike, Soehartati Argadikoesoema Gondhowiardjo, Kathryn D. Held, Takashi Nakano, Atsushi Shibata · 2019 · Oncogene
  33. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
    Bin Zhang, Ping Cheng · 2020 · Molecular Cancer
  34. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
    Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Takeru Funakoshi, Taku Fujimura, Yuki Yamamoto, Hiroo Hata, Masahiko Gosho, Ryota Tanaka, Kei Yamaguchi et al. · 2017 · Journal of Dermatological Science
  35. Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
    Samaan, Mark A., Pavlidis, Polychronis, Papa, Sophie, Powell, Nick, Irving, Peter M. · 2018 · Nature Reviews Gastroenterology & Hepatology
  36. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
    Yaping Chen, Xiao Zheng, Changping Wu · 2021 · Frontiers in Immunology
  37. Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?
    Marie-Léa Gauci, Barouyr Baroudjian, Charlotte Zeboulon, Cécile Pagès, Nicolas Poté, Olivier Roux, Mohamed Bouattour, Célèste Lebbé · 2018 · Journal of Hepatology
  38. Renal complications of immune checkpoint blockade
    Naoka Murakami, Shveta S. Motwani, Leonardo V. Riella · 2016 · Current Problems in Cancer
  39. Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer
    Noelia Rivera, Aram Boada, María Isabel Bielsa, María Teresa Fernández‐Figueras, Enric Carcereny, Teresa Morán, Carlos Ferrándiz · 2017 · JAMA Dermatology
  40. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
    Matteo Salvatore Carlino, Georgina Venetia Long, Dirk Schadendorf, Caroline Robert, Antoni Ribas, Erika Richtig, Marta Nyakas, Christian Caglevic, Ahmed Tarhini, Christian U. Blank et al. · 2018 · European Journal of Cancer
  41. Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
    Maxime Frélaut, Pauline du Rusquec, Alexandre De Moura, Christophe Le Tourneau, Édith Borcoman · 2020 · BioDrugs
  42. TIGIT, a novel immune checkpoint therapy for melanoma
    Wei Tang, Jun Chen, Tianlong Ji, Xiufeng Cong · 2023 · Cell Death and Disease
  43. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
    E. M. Hersh, Michele Del Vecchio, Michael Paul Brown, Richard F. Kefford, Carmen Loquai, Alessandro Testori, Shailender Bhatia, Ralf Gutzmer, Robert Martin Conry, Andrew Mark Haydon et al. · 2015 · Annals of Oncology
  44. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials
    Seongseok Yun, Nicole D. Vincelette, Myke R. Green, Andrea E. Wahner Hendrickson, Ivo L Abraham · 2016 · Cancer Medicine
  45. The development of immunotherapy in older adults: New treatments, new toxicities?
    Carole Hélissey, Cécile Vicier, Stéphane Champiat · 2016 · Journal of Geriatric Oncology
  46. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination
    A. Aboudaram, A. Modesto, Léonor Chaltiel, Carlos Gomez‐Roca, Serge Boulinguez, Vincent Sibaud, Jean‐Pierre Delord, Ciprian Chira, Martine Delannes, Elizabeth Cohen‐Jonathan Moyal et al. · 2017 · Melanoma Research
  47. Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
    Je‐Keun Rhee, Yu Chae Jung, Kyu Ryung Kim, Jinseon Yoo, Jeeyoon Kim, Yongjae Lee, Yoon Ho Ko, Han Hong Lee, Byoung Chul Cho, Tae‐Min Kim · 2017 · Cancer Immunology Research
  48. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
    Robert J. Torphy, Richard David Schulick, Yuwen Zhu · 2017 · International Journal of Molecular Sciences
  49. Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
    Alberto Carretero-González, David Lora, Ismael Ghanem, Jon Zugazagoitia, Daniel Castellano, Juan Manuel Sepúlveda-Sánchez, Jose Antonio Lopez-Martin, Luis G Paz-Ares, Guillermo de Velasco · 2018 · Oncotarget
  50. Intestinal microbiota: a new force in cancer immunotherapy
    Zhujiang Dai, Jingqiu Zhang, Qi Wu, Huiwen Fang, Chunfeng Shi, Zhen Li, Chaobiao Lin, Dong Tang, Daorong Wang · 2020 · Cell Communication and Signaling
  51. Cellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion
    Verdon, Daniel J., Mulazzani, Matthias, Jenkins, Misty R. · 2020 · International Journal of Molecular Sciences
  52. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
    Xingcheng Yang, Ling Ma, Xiaoying Zhang, Liang Huang, Jia Wei · 2022 · Experimental Hematology and Oncology
  53. New Strategies in Stereotactic Radiotherapy for Oligometastases
    David A. Palma, Alexander V. Louie, George Rodrigues · 2015 · Clinical Cancer Research
  54. Residual FDG ‐ PET metabolic activity in metastatic melanoma patients with prolonged response to anti‐ PD ‐1 therapy
    Benjamin Y. Kong, Alexander Maxwell Menzies, Catherine A.B. Saunders, Elizabeth Liniker, Sangeetha Ramanujam, Alexander David Guminski, Richard F. Kefford, Georgina Venetia Long, Matteo Salvatore Carlino · 2016 · Pigment Cell & Melanoma Research
  55. Renal effects of immune checkpoint inhibitors
    Hassan Izzedine, Christine Mateus, C. Boutros, Caroline Robert, Philippe Rouvier, Zahir Amoura, Alexis Mathian · 2016 · Nephrology Dialysis Transplantation
  56. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
    Mithunah Krishnamoorthy, Lara Gerhardt, Saman Maleki Vareki · 2021 · Cells
  57. Health-related quality of life results from the phase III CheckMate 067 study
    Dirk Schadendorf, James Larkin, Jedd D. Wolchok, Frank Stephen Hodi, Vanna Chiarion‐Sileni, Rene C. Gonzalez, Piotr Lukasz Rutkowski, Jean‐Jacques Grob, Charles Lance Cowey, Christopher D. Lao et al. · 2017 · European Journal of Cancer
  58. Aging, immune senescence, and immunotherapy: a comprehensive review
    Elias, Rawad, Hartshorn, Kevan, Rahma, Osama, Lin, Nina, Snyder-Cappione, Jennifer E. · 2018 · Seminars in Oncology
  59. Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
    Okada, Naoto, Kawazoe, Hitoshi, Takechi, Kenshi, Matsudate, Yoshihiro, Utsunomiya, Ryo, Zamami, Yoshito, Goda, Mitsuhiro, Imanishi, Masaki, Chuma, Masayuki, Hidaka, Noriaki et al. · 2019 · Clinical Therapeutics
  60. Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
    Douglas Buckner Johnson, Eirini Pectasides, Emily Feld, Fei Ye, Shilin Zhao, Romany Anne Nilanthi Johnpulle, Ryan M. Merritt, David F. McDermott, Igor J. Puzanov, Donald P. Lawrence et al. · 2016 · Journal of Immunotherapy
  61. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
    Elisa A. Rozeman, Tim J. A. Dekker, John B.A.G. Haanen, Christian U. Blank · 2017 · American Journal of Clinical Dermatology
  62. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
    Mehmet Asım Bilen, Giselle Dutcher, Yuan Liu, Deepak Ravindranathan, Haydn Thomas Kissick, Bradley Curtis Carthon, Ömer Küçük, Wayne Bernard Harris, Viraj A. Master · 2018 · Clinical Genitourinary Cancer
  63. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
    Julien Adam, Emilie Louvet, Tony Sourisseau, Nicolas Dorvault, Marine Bernard, Elodie Maingot, Laura Faivre, Mei-Shiue Kuo, Émilie Boissier, Marie-Charlotte Dessoliers et al. · 2018 · ESMO Open
  64. Identifying and managing the adverse effects of immune checkpoint blockade
    Arthur Winer, Joseph Nicholas Bodor, Hossein Borghaei · 2018 · Journal of Thoracic Disease
  65. Immunomodulatory effects of CD38-targeting antibodies
    Niels W.C.J. van de Donk · 2018 · Immunology Letters
  66. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
    Paul Nathan, Paolo A. Ascierto, John B.A.G. Haanen, Enrique Espinosa, Лев Вадимович Демидов, Claus Garbe, Michele Guida, Paul C. Lorigan, Vanna Chiarion‐Sileni, Helen J Gogas et al. · 2019 · European Journal of Cancer
  67. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
    Tuba Nur Gide, Inês Pires da Silva, Camelia Y. J. Quek, Tasnia Ahmed, Alexander Maxwell Menzies, Matteo Salvatore Carlino, Robyn P.M. Saw, John F. Thompson, Marcel Batten, Georgina Venetia Long et al. · 2019 · OncoImmunology
  68. Review article: new therapeutic interventions for advanced hepatocellular carcinoma
    Saroja D. Bangaru, Jorge A. Marrero, Amit G. Singal · 2019 · Alimentary Pharmacology & Therapeutics
  69. Metabolic regulation of immune responses: therapeutic opportunities
    Nadine Aßmann, David K. Finlay · 2016 · Journal of Clinical Investigation
  70. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids
    Mirjana Ziemer, Εleni Κoukoulioti, Susanne Beyer, Jan Christoph Simon, Thomas Berg · 2016 · Journal of Hepatology
  71. Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer
    Yuki Iijima, Yosuke Hirotsu, Kenji Amemiya, Yoshihiko Ooka, Hitoshi Mochizuki, Toshio Oyama, Takahiro Nakagomi, Yoshinori Uchida, Yoichi Kobayashi, Toshiharu Tsutsui et al. · 2017 · European Journal of Cancer
  72. Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma
    Marco Tucci, Anna Maria Passarelli, Francesco Mannavola, Luigia Stefania Stucci, Paolo A. Ascierto, Mariaelena Capone, Gabriele Madonna, Patrizia Lopalco, Francesco Silvestris · 2017 · OncoImmunology
  73. Liquid biomarkers in melanoma: detection and discovery
    Su Yin Lim, Jenny Lee, Russell J. Diefenbach, Richard F. Kefford, Helen Rizos · 2018 · Molecular Cancer
  74. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
    Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata et al. · 2018 · Oncotarget
  75. PD ‐1 and PD ‐L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome
    Sven Schneider, Lorenz Kadletz, Robert Wiebringhaus, Lukas Kenner, Edgar Selzer, Thorsten Füreder, Orsolya Rajky, Anna Sophie Berghoff, Matthias Preusser, Gregor Heiduschka · 2018 · Histopathology
  76. Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity
    Huan Deng, Songwei Tan, Xueqin Gao, Chenming Zou, Chenfeng Xu, Kun Tu, Qingle Song, Fengjuan Fan, Wei Huang, Zhiping Zhang · 2019 · Acta Pharmaceutica Sinica B
  77. Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors
    Ohad Oren, Eric H. Yang, Julian R. Molina, Kent R. Bailey, Roger Scott Blumenthal, Stephen Louis Kopecky · 2020 · The American Journal of Cardiology
  78. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis
    Jiaying Wu, Dongsheng Hong, Xiangnan Zhang, Xiaoyang Lu, Jing Miao · 2017 · Scientific Reports
  79. The Cancer Immunotherapy Biomarker Testing Landscape
    Eric E. Walk, Sophia Louise Yohe, Amy Beckman, Andrew E. Schade, Mary M. Zutter, John D. Pfeifer, Anna Belinda Berry · 2019 · Archives of Pathology & Laboratory Medicine
  80. Immune checkpoint inhibitors to treat cutaneous malignancies
    Dulce M. Barrios M.S, Mytrang H. Do, Gregory S. Phillips, Michael Andrew Postow, Tomoko Akaike, Paul Nghiem, Mario E. Lacouture · 2020 · Journal of the American Academy of Dermatology
  81. Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function
    Lydia Dyck, Hannah Prendeville, Mathilde Raverdeau, Mieszko M. Wilk, Róisín M. Loftus, Aaron Douglas, Janet McCormack, Bruce Moran, Michael Wilkinson, Evanna L. Mills et al. · 2022 · The Journal of Experimental Medicine
  82. Resident memory T cells and cancer
    Noah Veis Gavil, Katarina Cheng, David Masopust · 2024 · Immunity
  83. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances
    Jonathan L. Messerschmidt, George C. Prendergast, Gerald L. Messerschmidt · 2016 · The Oncologist
  84. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
    Anna Śledzińska, Laurie Menger, Katharina F. Bergerhoff, Karl S. Peggs, Sergio A. Quezada · 2015 · Molecular Oncology
  85. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
    Arun Rajan, Chul Kim, Christopher Ryan Heery, Udayan Guha, James L. Gulley · 2016 · Human Vaccines & Immunotherapeutics
  86. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
    Xiao-yi Tang, Yao Sun, Ang Zhang, Guoliang Hu, Wei William Cao, Danhong Wang, Bin Zhang, Hu Chen · 2016 · BMJ Open
  87. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies
    Joseph J. Jennings, Rohan H. Mandaliya, Ahmad Nakshabandi, James H. Lewis · 2019 · Expert Opinion on Drug Metabolism & Toxicology
  88. Cardiac Complications in Immune Checkpoint Inhibition Therapy
    Kazuko Tajiri, Masaki Ieda · 2019 · Frontiers in Cardiovascular Medicine
  89. Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
    Nethanel Asher, Guy Ben‐Betzalel, Shaked Lev Ari, Ronnie Shapira‐Frommer, Yael Steinberg‐Silman, Neta Gochman, Jacob Schachter, Tomer Meirson, Gal Markel · 2020 · Cancers
  90. Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy
    Quan Liu, Yanhong Duo, Jianye Fu, Meng Qiu, Zhe Sun, Dickson Adah, Jianlong Kang, Zhongjian Xie, Taojian Fan, Shiyun Bao et al. · 2020 · Nano Today
  91. Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts
    Xiaowen Huang, Muni Hu, Tiantian Sun, Jiantao Li, Yilu Zhou, Yuqing Yan, Baoqin Xuan, Jilin Wang, Hua Xiong, Linhua Ji et al. · 2023 · Cell Host & Microbe
  92. Nivolumab for the treatment of cancer
    Anasuya Gunturi, David F. McDermott · 2014 · Expert Opinion on Investigational Drugs
  93. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
    Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, Caroline Robert, Omid Hamid, ADIL I. DAUD, Alfons J.M. van den Eertwegh, Lee D. Cranmer, Steven J O'Day, Igor J. Puzanov et al. · 2016 · European Journal of Cancer
  94. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
    Jun Guo, Shukui Qin, Jun Liang, Tongyu Lin, Lu Si, Xiaohong Chen, Zhihong Chi, Chuanliang Cui, Nan Du, Yun Fan et al. · 2016 · Chinese Clinical Oncology
  95. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
    Elizabeth Stephanie Ahern, Heidi Harjunpää, Jake S. O’Donnell, Stacey M. Allen, William C. Dougall, Michele W.L. Teng, Mark John Smyth · 2018 · OncoImmunology
  96. 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
    Paolo A. Ascierto, Francesco Maria Marincola · 2015 · EBioMedicine
  97. Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor
    Shin Foong Ngiow, Arabella Young, Stephen J. Blake, Geoffrey R. Hill, Hideo Yagita∥, Michele W.L. Teng, Alan J. Korman, Mark John Smyth · 2016 · Cancer Research
  98. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
    Winson S. Ho, Herui Wang, Dominic M. Maggio, John S. Kovach, Qi Zhang, Qi Song, Francesco Maria Marincola, John D. Heiss, Mark R. Gilbert, Rongze Olivia. Lu et al. · 2018 · Nature Communications
  99. Time to dissect the autoimmune etiology of cancer antibody immunotherapy
    Michael Lawrence Dougan, Massimo Pietropaolo · 2020 · Journal of Clinical Investigation
  100. Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo
    Huapan Fang, Zhaopei Guo, Jie Chen, Lin Lin, Yingying Hu, Yanhui Li, Huayu Tian, Xuesi Chen · 2021 · Nature Communications